ARTICLE | Company News
ZymoGenetics, Novo Nordisk deal
October 11, 2004 7:00 AM UTC
NVO received exclusive worldwide rights to develop and commercialize ZGEN's rFactor XIII portfolio, including all related IP. NVO will pay $15 million in cash on signing and up to $62 million in miles...